File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

TitleCumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review
Authors
Keywordscisplatin
concurrent chemoradiotherapy
cumulative dose
outcome
radiotherapy
Issue Date2015
Citation
Head Neck, 2015 How to Cite?
AbstractBACKGROUND: The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. METHODS: The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. RESULTS: Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p = .027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. CONCLUSION: Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival. (c) 2015 Wiley Periodicals, Inc. Head Neck, 2015.
Persistent Identifierhttp://hdl.handle.net/10722/220019
ISSN
2015 Impact Factor: 2.76
2015 SCImago Journal Rankings: 1.233

 

DC FieldValueLanguage
dc.contributor.authorStrojan, P-
dc.contributor.authorVermorken, JB-
dc.contributor.authorBeitler, JJ-
dc.contributor.authorSaba, NF-
dc.contributor.authorHaigentz, M., Jr.-
dc.contributor.authorBossi, P-
dc.contributor.authorWorden, FP-
dc.contributor.authorLangendijk, JA-
dc.contributor.authorEisbruch, A-
dc.contributor.authorMendenhall, WM-
dc.contributor.authorLee, WMA-
dc.contributor.authorHarrison, LB-
dc.contributor.authorBradford, CR-
dc.contributor.authorSmee, R-
dc.contributor.authorSilver, CE-
dc.contributor.authorRinaldo, A-
dc.contributor.authorFerlito, A-
dc.date.accessioned2015-10-16T06:16:23Z-
dc.date.available2015-10-16T06:16:23Z-
dc.date.issued2015-
dc.identifier.citationHead Neck, 2015-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/220019-
dc.description.abstractBACKGROUND: The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. METHODS: The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. RESULTS: Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p = .027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. CONCLUSION: Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival. (c) 2015 Wiley Periodicals, Inc. Head Neck, 2015.-
dc.languageeng-
dc.relation.ispartofHead Neck-
dc.subjectcisplatin-
dc.subjectconcurrent chemoradiotherapy-
dc.subjectcumulative dose-
dc.subjectoutcome-
dc.subjectradiotherapy-
dc.titleCumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review-
dc.typeArticle-
dc.identifier.emailLee, WMA: awmlee@hkucc.hku.hk-
dc.identifier.authorityLee, WMA=rp02056-
dc.identifier.doi10.1002/hed.24026-
dc.identifier.pmid25735803-
dc.identifier.hkuros265758-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats